|Chemical and physical data|
|Molar mass||186.252 g·mol−1|
|3D model (JSmol)|
Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.
- Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, et al. (March 2000). "Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist". Pharmaceutica Acta Helvetiae. 74 (2–3): 125–30. doi:10.1016/S0031-6865(99)00024-2. PMID 10812948.
- Wagner FF, Comins DL (October 2006). "Expedient five-step synthesis of SIB-1508Y from natural nicotine". The Journal of Organic Chemistry. 71 (22): 8673–5. doi:10.1021/jo0616052. PMID 17064057.
- Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND (October 2008). "Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist". Brain Research. 1234: 16–24. doi:10.1016/j.brainres.2008.07.063. PMID 18692487.
- The Parkinson Study Group (February 2006). "Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease". Neurology. 66 (3): 408–10. doi:10.1212/01.wnl.0000196466.99381.5c. PMID 16476941.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|